 |
SV Life Sciences Fund I (SVLSFI)SVLSF I closed in 1994 with total commitments of $100 million. As at 31 December 2006, SVLSF I had invested $123 million in 31 portfolio companies. To go to individual portfolio companies websites please click on company
logo. 
Axys Pharmaceuticals: USFirst investment: 1994 - Early Stage - Exited Protease-inhibitor based products for cancer & inflammatory diseases. 
Cerebrus: UKFirst investment: 1995 - Start Up - Exited CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis) 
Cytomed: USFirst investment: 1997 - Early Stage - Exited Leukotriene inhibitors for asthma (Acquired by LeukoSite Inc and then by Millenium). 
Geltex Pharmaceuticals: USFirst investment: 1995 - Early Stage - Exited Further investment: 1998 - Expansion - Exited Development of novel non-absorbed pharmaceuticals. Acquired by Genzyme Corporation after our exit. 
Incyte Pharmaceuticals: UKFirst investment: 1996 - Start Up - Exited Functional genomics (Acquired by Incyte). 
Kinetix Pharmaceuticals: USFirst investment: 1999 - Start Up - Exited Kinase targeted drug discovery (Acquired by Amgen).
LeukoSite: USFirst investment: 1994 - Start Up - Exited Treatment of Inflammatory diseases and cancer (Acquired by Millenium). 
Metris Therapeutics: UKinvestment SVLSF I: 1998 - Start Up investment SVLSF II: 2000 Treatment of gynaecological disorders. 
Micromet: GermanyFirst investment: 1998 - Start Up Drug discovery using novel protein drugs 
Shire Pharmaceuticals: USFirst investment: 1994 - Early Stage - Exited Osteoporosis and Alzheimer's disease. 
Strides Arcolab: IndiaFirst investment: 1997 - Expansion - Exited Manufacturer of generic pharmaceuticals. 
Triangle Pharmaceuticals: USFirst investment: 1995 - Start Up - Exited Antiviral and anticancer drug development (Acquired by Gilead).
Vanguard Medica (Vernalis): UKFirst investment: 1995 - Early Stage - Exited Antiviral and anticancer drug development. (Acquired by Vernalis) 
|
